Myoferlin gene silencing decreases Tie-2 expression in vitro and angiogenesis in vivo

Carol Yu1, Arpeeta Sharma, Andy Trane

  • 1The Providence Heart and Lung Institute, The James Hogg Research Centre, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Insights

Myoferlin knockdown in endothelial cells reduces expression of key angiogenic receptors, demonstrating its role in new blood vessel growth. Acute Myoferlin silencing in mice effectively inhibits angiogenesis and edema, validating it as a therapeutic target.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial in diseases like cancer, but current anti-angiogenesis therapies are only partially effective.
  • Identifying novel modulators of angiogenesis is essential for developing improved therapeutic strategies.
  • Myoferlin, a transmembrane protein, was recently identified in endothelial cells and implicated in lipid vesicle fusion and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) expression.

Purpose of the Study:

  • To investigate the role of Myoferlin in regulating angiogenic receptors beyond VEGFR-2.
  • To determine if acute Myoferlin knockdown exhibits anti-angiogenic effects in vivo.
  • To validate Myoferlin as a potential therapeutic target for anti-angiogenesis strategies.

Main Methods:

  • Gene silencing of Myoferlin in cultured endothelial cells (EC).
  • Assessment of tyrosine kinase receptor expression (VEGFR-2 and Tie-2) following Myoferlin knockdown.
  • In vivo delivery of Myoferlin siRNA in mouse tissues to evaluate effects on angiogenesis and edema formation.

Main Results:

  • Myoferlin gene silencing in EC led to decreased expression of both VEGFR-2 and Tie-2, key receptors involved in angiogenesis.
  • Acute knockdown of Myoferlin in mouse tissues using siRNA resulted in significant attenuation of angiogenesis.
  • Myoferlin silencing also reduced edema formation in mouse tissues, suggesting a role in vascular permeability.

Conclusions:

  • Myoferlin plays a critical role in maintaining the expression of essential angiogenic receptors, including Tie-2, at the plasma membrane of endothelial cells.
  • Acute Myoferlin knockdown demonstrates significant anti-angiogenic effects in vivo, validating Myoferlin as a novel therapeutic target.
  • These findings support the concept that Myoferlin is essential for proper tyrosine kinase receptor expression and function in angiogenesis.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...